{"filings":[{"id":2190157,"accession_number":"0001193125-26-344748","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-08-11T20:23:00+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q2 2026 revenue down 23% to $3.1M; net loss $16.9M; reaffirms FY26 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.1M vs $4.1M in Q2 2025, a 23% decline on macro headwinds and longer sales cycles.","Net loss narrowed to $16.9M from $19.4M; operating expenses fell 19% to $18.3M.","Cash, equivalents and investments ~$209.5M at June 30, 2026; repurchased ~200,000 shares.","Reaffirms FY2026 revenue guidance of $16M-$18M, implying ~3% growth at midpoint.","Initiated ITC investigation against Nanomics for alleged patent infringement on Proteograph."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1996237,"accession_number":"0001193125-26-328733","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-07-31T20:35:34+00:00","items":["5.07"],"status":"ready","headline":"Seer CEO Omid Farokhzad proposes to take company private at $2.45/share plus two CVRs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["CEO Omid Farokhzad proposes to acquire all outstanding shares for $2.45/share cash plus two CVRs (Revenue-Linked up to $0.25, Sale-Linked up to $2.91).","Cash consideration represents 41% premium to 30-day VWAP; aggregate potential value up to 222% premium.","Proposal not subject to financing contingency; board to form Special Committee of independent directors to evaluate.","CEO acknowledges conflict of interest and will recuse from board deliberations; proposal presented as superior to Radoff-JEC alternative.","CVRs tied to revenue milestones in 2031 and future sale of company within 5 years; no dilution from future equity financings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1977396,"accession_number":"0001193125-26-326858","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-07-31T11:47:20+00:00","items":["8.01","9.01"],"status":"ready","headline":"Seer receives two revised buyout proposals: CEO offers $2.45/share + CVRs; Radoff-JEC offers $2.55/share + CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["CEO Omid Farokhzad proposes $2.45/share cash plus two CVRs (revenue-linked up to $0.33, sale-linked up to $4.91), total potential $7.69/share.","Radoff-JEC Group offers $2.55/share cash plus one contingent value right (CVR) with terms not disclosed.","CEO's cash offer represents 41% premium to 30-day VWAP; aggregate potential including CVRs is 342% premium.","Special Committee will review both proposals; no stockholder action required now; CEO's proposal not subject to financing contingency.","CEO aims to close by end of September 2026 via two-step tender offer merger; CVRs expire in 2033."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1748197,"accession_number":"0001193125-26-308919","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-07-20T20:08:49+00:00","items":["8.01","9.01"],"status":"ready","headline":"Seer Board Special Committee Rejects CEO Farokhzad's $2.45/Share Buyout Bid","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Committee unanimously rejects unsolicited proposal from CEO Omid Farokhzad to acquire all shares for $2.45/share cash plus two CVRs.","Proposal received July 1, 2026; committee determined it undervalues Seer and fails to reflect long-term growth prospects.","Special Committee consists of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D.; they consulted independent advisors.","Contingent value rights were deemed insufficient to fully value Seer's technology and growth potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1417677,"accession_number":"0001193125-26-294994","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-07-02T21:28:57+00:00","items":["8.01","9.01"],"status":"ready","headline":"Seer CEO Omid Farokhzad proposes to take company private at $2.45/share cash plus two CVRs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["CEO Omid Farokhzad offers $2.45/share cash (41% premium to 30-day VWAP) plus Revenue-Linked CVR up to $0.25/share and Sale-Linked CVR up to $2.91/share.","Board will form Special Committee of independent directors to evaluate proposal; CEO recused from deliberations.","Proposal not subject to financing contingency; CEO claims it is superior to competing Radoff-JEC offer at same cash price.","CVRs tied to 2031 revenue milestones and future sale of company within 5 years; aggregate potential consideration represents 222% premium.","CEO commits to remain with company, retain leadership, and accelerate Proteograph platform investment if deal closes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":591756,"accession_number":"0001193125-26-235517","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-05-22T12:11:43+00:00","items":["8.01","9.01"],"status":"ready","headline":"Seer Board Unanimously Rejects $2.40/Share Cash Plus CVR Bid from Radoff-JEC Group","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Board unanimously rejected May 14 revised proposal at $2.40/share cash plus contingent value right.","Proposal implies equity value below sum of Seer's cash, cash equivalents and investments.","Board determined proposal significantly undervalues Seer's long-term growth prospects.","Proposal is materially the same as the one rejected by the Board on April 27, 2026.","Seer advised by Perella Weinberg Partners and Wilson Sonsini Goodrich & Rosati."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68644,"accession_number":"0001193125-26-221696","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-05-13T20:19:36+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q1 2026 revenue $2.8M (-34% YoY); reaffirms FY2026 guidance of $16M-$18M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.8M, down 34% from $4.2M YoY, driven by depressed academic funding and competitive activity.","Net loss $16.8M vs $19.9M prior year; operating expenses down 20% to $18.2M.","Reaffirmed full year 2026 revenue guidance of $16M-$18M (3% growth at midpoint).","Ended Q1 with ~$220M cash and investments; repurchased ~1.5M shares in the quarter.","Appointed Anthony (Tony) Bazarko as CCO; secured collaboration with Precision Health Research, Singapore (10,000 samples)."],"consensus_eps_estimate":-0.3009,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":2793000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95026,"accession_number":"0001193125-26-204084","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Seer appoints Anthony Bazarko as Chief Commercial Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony Bazarko named CCO effective May 4, 2026; previously President & CEO of Biologos and CCO at Specific Diagnostics.","Bazarko brings over 20 years of commercial leadership in life sciences, diagnostics, and biotech.","He will lead Seer's Sales, Marketing, and Customer Experience to accelerate Proteograph Product Suite adoption.","CEO Omid Farokhzad cites Bazarko's record of commercial strategy as key to next growth phase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95025,"accession_number":"0001193125-26-182155","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Seer Board unanimously rejects revised $2.35/share takeover bid from Radoff-JEC Group","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Revised proposal from Radoff/JEC offers $2.35/share plus contingent value right; board says significantly undervalues Seer.","Board claims implied equity value is below Seer's current cash, cash equivalents and investments.","Seer highlights 240 patent filings, 80+ peer-reviewed publications, and SGK100 biobank study as evidence of momentum.","Board will evaluate Radoff-JEC's director nominees per bylaws; no action required from stockholders now."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95024,"accession_number":"0001193125-26-152998","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Seer receives unsolicited $2.25/share buyout proposal from Radoff-JEC Group","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Radoff-JEC Group proposed to acquire all Seer shares for $2.25 per share cash plus a contingent value right.","Board will review the unsolicited, non-binding proposal with financial and legal advisors.","Radoff-JEC Group nominated three director candidates for election at the 2026 annual meeting.","No stockholder action required now; formal Board recommendation to be included in proxy statement.","2026 Annual Meeting date has not yet been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107802,"accession_number":"0001193125-26-131802","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PTAB upholds 23 claims of Seer's particle proteomics patent in Bruker challenge","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["PTAB Final Written Decision on March 23, 2026, upholds five challenged and 18 unchallenged claims of U.S. Patent No. 11,435,360.","Patent covers protein enrichment using engineered nano- and microparticles, core to Seer's Proteograph platform.","Petitioners PreOmics GmbH and Biognosys AG (Bruker subsidiaries) failed to show unpatentability of claims 2,3,7,23,24.","Six claims (1,4,6,22,24,25) were found unpatentable; appeal deadline is May 25, 2026.","'360 patent is owned by Brigham and Women's Hospital and exclusively licensed to Seer; CEO vows continued IP defense."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107801,"accession_number":"0001193125-26-107335","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Seer amends Tax Benefit Preservation Plan, pays $250K mootness fee to settle suit","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Amended definition of 'Beneficial Ownership' in Tax Benefit Preservation Plan to address stockholder lawsuit.","Lawsuit Taylor v. Farokhzad (Del. Chancery) challenged Plan's definition; company believes allegations meritless.","Agreed to pay $250,000 mootness fee to avoid litigation costs; Delaware Action to be dismissed as moot.","Amendment clarifies interaction with Treasury Regulation § 1.382-3(a)(1); effective March 13, 2026.","Settlement fully satisfies all claims for attorneys' fees, costs, and expenses in the Delaware Action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107800,"accession_number":"0001193125-26-076684","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["1.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Seer adopts tax-benefit preservation plan (poison pill) to protect NOLs; triggers at 4.9% ownership","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board declared dividend of one Right per common share, record date March 9, 2026.","Rights become exercisable at $11.00 each for 1/1000th Series A Preferred after trigger.","Plan deters acquisition of 4.9% or more common stock without Board approval.","Plan expires on February 25, 2029, unless extended or NOLs are fully utilized.","Adopted to preserve net operating losses and tax attributes under Section 382 of the Code."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107799,"accession_number":"0001193125-26-076580","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q4 revenue $4.2M (+5% YoY); FY 2026 guidance $16-18M implies ~3% midpoint growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $4.2M, up 5% YoY from $4.0M; product revenue $2.8M, service $1.2M.","Full-year 2025 revenue $16.6M (+17% YoY vs $14.2M); net loss $73.6M, improved from $86.6M.","Installed base reached 82 instruments (+67% YoY); 33 instruments placed in FY 2025.","Cash & investments $240.6M at Dec 31, 2025; operating expenses down 23% in Q4 to $19.6M.","FY 2026 revenue guidance $16M-$18M; CEO cites persistent NIH funding uncertainty as headwind."],"consensus_eps_estimate":-0.3264,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":16578000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124202,"accession_number":"0001193125-25-317535","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Seer converts all Class B stock to Class A, ending dual-class voting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All outstanding Class B shares automatically converted into Class A on a 1:1 basis at close of business Dec. 9, 2025.","Following conversion, Class B shares retired; authorized capital reduced via Certificate of Retirement filed Dec. 12, 2025.","Each prior Class B share had ten votes; now holders have one vote per share under Class A.","Economic interests unchanged; stock continues trading on Nasdaq under ticker SEER."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124201,"accession_number":"0001193125-25-269705","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q3 2025 revenue $4.1M, net loss $18.2M; reaffirms FY25 revenue guidance $17-18M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.1M (+2% YoY); product revenue $2.8M, service revenue $1.2M, including $300K related party.","Gross margin 51%; operating expenses $21.5M (down 18% YoY) driven by lower stock-based comp and costs.","Net loss $18.2M vs $21.3M Q3 2024; cash, equivalents and investments $251.2M.","Shipped nearly 3x instruments in first 9 months of 2025 compared to all of 2024; record publications.","FY2025 revenue guidance reaffirmed at $17M-$18M, representing ~24% growth at midpoint over FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":12377000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140863,"accession_number":"0001726445-25-000006","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Seer appoints Isaac Ro to Board of Directors; grants initial equity award","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Isaac Ro appointed to Seer board effective Sept 2, 2025, also named to Audit Committee as financial expert.","Initial equity award granted: option for 61,000 shares and RSU for 41,000 shares, vesting over 3 years.","Ro is Partner at Catalio Capital Management; previously CFO at Sema4 and Thrive Earlier Detection.","Appointment resolves any potential non-compliance with Nasdaq listing rules regarding audit committee financial expert."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140862,"accession_number":"0000950170-25-104072","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q2 revenue $4.1M (+32% YoY); launches Proteograph ONE & SP200","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $4.1M for Q2 2025, up 32% from $3.1M a year ago, driven by product and service revenue.","Net loss narrowed to $19.4M from $22.9M; operating expenses down 21% to $22.6M.","Cash, equivalents and investments of $263.3M as of June 30, 2025.","Full-year 2025 revenue guidance reaffirmed at $17M-$18M (24% midpoint growth).","Launched high-throughput Proteograph ONE assay and SP200 automation instrument."],"consensus_eps_estimate":-0.3774,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":8256000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140861,"accession_number":"0000950170-25-094597","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["3.01","5.07"],"status":"ready","headline":"Seer non-compliant with Nasdaq Audit Committee rule after annual meeting; cure period sought","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On July 7, 2025, notified Nasdaq that post-annual meeting it will not comply with Rule 5605(c)(2)(A) requiring at least three Audit Committee members, one with financial sophistication.","Intends to rely on cure period under Rule 5605(c)(4)(B) and expects to regain compliance before expiration.","Annual meeting elected all six director nominees: Farokhzad, Gulyani, McGuire, Langer, Nishar, Roelofs (withheld votes ranged from 0.6M to 10.0M).","Stockholders ratified Deloitte & Touche as independent auditor for FY2025 with 85.9M votes for, 4,444 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158603,"accession_number":"0000950170-25-070359","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q1 revenue $4.2M (+37% YoY); ships as many instruments as all of 2024; reaffirms FY25 guidance $17-18M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.2M, up 37% from $3.1M YoY, driven by higher product sales and service revenue.","Net loss $19.9M vs $20.7M YoY; operating expenses down 14% to $22.8M.","Cash, equivalents and investments ~$285M at quarter end.","Q1 instrument shipment volume equaled full-year 2024; 10,000-sample contract with new customer announced.","Full-year 2025 revenue guidance reaffirmed at $17M-$18M (24% growth at midpoint)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":4205000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177008,"accession_number":"0000950170-25-029140","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q4 revenue down 10% YoY to $4.0M; full-year net loss $86.6M; guides 2025 rev $17-18M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $4.0M (-10% YoY); full-year 2024 revenue $14.2M (-15% YoY).","Q4 net loss $21.7M vs $17.8M YoY; full-year net loss $86.6M vs $86.3M.","Shipped 10 instruments in 2024; cumulative 72. Ended with ~$300M cash/investments.","Repurchased ~6.5M shares at avg $1.82/share in 2024, reducing shares by ~10%.","Expects 2025 revenue $17-18M, representing ~24% growth at midpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":14170000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193790,"accession_number":"0000950170-24-122309","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q3 2024 revenue $4.0M, net loss $21.3M; FY guidance reaffirmed $13-15M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $4.0M vs $4.2M YoY (down 3%); product revenue $3.1M, service $847K, grant $90K.","Net loss $21.3M vs $21.1M YoY; gross margin 48%; operating expenses down 6% to $26.3M.","Repurchased 3.7M shares at avg $1.78 in Q3; total 5.7M shares repurchased to date.","Entered co-marketing agreement with Thermo Fisher Scientific for Proteograph suite with Orbitrap Astral mass specs.","Cash, equivalents & investments $312M; FY 2024 revenue guidance reaffirmed at $13-15M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":10170000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193789,"accession_number":"0000950170-24-112982","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Seer reprices ~7.9M underwater options to $2.00; CEO/CFO affected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved repricing of ~7.9M underwater options (original strike $2.08-$60.15) to $2.00 per share.","CEO Omid Farokhzad repriced options on 2,732,470 shares; CFO David Horn on 1,140,454 shares.","Performance-based options with $6.89 hurdle amended to $3.00 (150% of $2.00) for 790,000 shares.","Repriced options have retention period through Apr 4, 2026; early exercise triggers original premium price.","Board decided no additional equity awards in 2025 to executive officers SVP and above."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210122,"accession_number":"0000950170-24-098074","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Seer appoints Nicolas Roelofs to board as Lead Independent Director effective Aug 13, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Roelofs replaces David Hallal as Lead Independent Director and joins CG&N and Science & Technology committees.","Initial equity award of 69,470 stock options and 46,886 RSUs, vesting in three equal annual installments.","Roelofs brings 35+ years experience including president of Agilent Life Sciences Group.","No arrangement or understanding with any person regarding his election as director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210121,"accession_number":"0000950170-24-094022","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q2 revenue $3.1M (-23% YoY); FY 2024 guidance cut to $13-15M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.1M, down 23% YoY from $4.0M; product revenue $2.2M, service $845K.","Net loss $22.9M vs $23.4M prior year; operating expenses $28.8M (down 5% YoY).","Full-year 2024 revenue guidance reduced to $13M-$15M from prior $16M-$18M.","Launched Seer Technology Access Center (STAC) in Europe; customer papers in Nature.","Cash, equivalents and investments $344.6M as of June 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":6138000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210120,"accession_number":"0000950170-24-084935","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Seer CLO resigns; David Hallal appointed to Audit Committee, resolving Nasdaq compliance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elona Kogan resigns as Chief Legal Officer and Corporate Secretary effective July 26, 2024; departure not related to any disagreement.","David Hallal appointed to Audit Committee on July 19, 2024; qualifies as audit committee financial expert.","Appointment follows Rachel Haurwitz's resignation from Board, which caused non-compliance with Nasdaq Listing Rule 5605(c)(2)(A).","Company believes Hallal's appointment resolves potential non-compliance with Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210119,"accession_number":"0000950170-24-083207","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Seer director resigns; company out of compliance with Nasdaq Audit Committee rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Dr. Rachel Haurwitz resigned from Seer's Board and all committees effective July 8, 2024.","Company notified Nasdaq on July 11 that it no longer meets Listing Rule 5605(c)(2)(A) for Audit Committee.","Seer intends to rely on cure period under Rule 5605(c)(4)(B) and is evaluating board composition to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228360,"accession_number":"0000950170-24-073743","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Seer stockholders elect four directors and ratify Deloitte as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum achieved with 82.8M votes representing 81.7% of eligible votes.","Elected Omid Farokhzad, Meeta Gulyani, David Hallal, Terrance McGuire; each >66M votes for.","Ratified Deloitte & Touche LLP as auditor for FY2024; 82.7M for, 23.8K against, 69.8K abstain.","All proposals passed; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228359,"accession_number":"0000950170-24-055694","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q1 revenue down 24% YoY to $3.1M; net loss narrows to $20.7M; authorizes $25M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.1M (-24% YoY); product revenue $2.5M (incl. $828K related party), service $534K.","Net loss $20.7M improved from $24.0M; gross margin 44%; operating expenses $26.6M (-10% YoY).","Cash and investments $359.2M; board authorized up to $25M share repurchase program.","FY2024 revenue guidance of $16M-$18M, essentially flat vs FY2023 revenue.","Expanding Proteograph STAC program to Europe; three new peer-reviewed publications supporting platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":3066000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247070,"accession_number":"0000950170-24-023099","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer reports Q4 revenue down 4% YoY to $4.4M; FY revenue up 8% to $16.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $17.8M narrowed from $22.5M; FY net loss $86.3M vs $93.0M prior year.","Cash, equivalents and investments totaled $373.1M as of Dec 31, 2023.","FY 2024 revenue guided to $18M-$20M, representing ~14% growth at midpoint.","Cumulative instruments shipped reached 62; 23 shipped in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":16661000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264508,"accession_number":"0000950170-23-072638","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Seer director Catherine Friedman resigns; board reduced to 7; audit chair changed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Catherine Friedman resigned from the Board effective December 21, 2023, reducing board size from 8 to 7.","Rachel Haurwitz, Ph.D. appointed to Audit Committee; determined independent and an audit committee financial expert.","Meeta Gulyani appointed Chair of the Audit Committee.","No reason for Friedman's resignation disclosed; no compensatory changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264507,"accession_number":"0001628280-23-039503","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Seer promotes David Horn to President, appoints Elona Kogan as Chief Legal Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Horn (CFO & Treasurer) adds President role; Omid Farokhzad resigns as President but remains CEO and Chair.","Horn's base salary increased to $510,000; target bonus raised to 55% of salary, pro-rated for FY2023.","Elona Kogan, previously General Counsel and Corporate Secretary, appointed Chief Legal Officer effective Nov 17, 2023.","Kogan has served as GC since Nov 2020; prior roles include GC at Selecta Biosciences, ARIAD, and Avanir."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264506,"accession_number":"0001628280-23-037369","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q3 revenue $4.2M (+5% YoY), net loss $21.1M; guides to lower half of FY range","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.2M (+5% YoY); product revenue $3.3M incl $1.4M related party; service $536K; grant $348K.","Net loss $21.1M vs $24.0M YoY; operating expenses $28.0M with $8.3M stock-based compensation.","Cash and investments $380.8M at Sep 30, 2023.","FY 2023 revenue guided to lower half of $16-18M range due to ongoing macroeconomic headwinds.","Expanded geographically with Danyel Biotech (Israel) and GeneTiCA (Eastern Europe); added Panome Bio as Center of Excellence."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":12223000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281744,"accession_number":"0001628280-23-028203","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q2 revenue $4M (+11% YoY); slashes FY2023 guidance to $16-18M from $23-25M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $23.4M from $22.8M YoY; operating expenses rose 21% to $30.2M.","Product-related revenue $3.0M including $1.4M related party; service revenue $467K; grant $538K.","Cash, equivalents and investments at $396M as of June 30, 2023.","Launched Proteograph XT Assay Kit and STAC service; expanded Thermo Fisher collaboration.","Guidance cut: now expects FY2023 revenue $16-18M (prior $23-25M), 10% growth at midpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":8061000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281743,"accession_number":"0001628280-23-025344","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2023-07-21T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Seer board member Mostafa Ronaghi resigns effective immediately; board size reduced to 8","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mostafa Ronaghi, Ph.D. resigned from Seer's Board of Directors and all committees on July 18, 2023.","Board size decreased from nine to eight members following the resignation.","CEO Omid Farokhzad thanked Dr. Ronaghi for his contributions; Dr. Ronaghi expressed pride in company's accomplishments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300708,"accession_number":"0001628280-23-022349","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Seer shareholders approve board declassification; two directors receive over 24% withhold votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Declassification proposal approved: 77.5M for, 5.9K against, 4.0M broker non-votes; certificate amended June 14.","Deloitte & Touche ratified as auditor with 81.5M votes for.","Advisory vote on executive compensation passed: 60.8M for, 12.3M against, 4.4M abstentions.","Four directors elected; Hallal (70.1%) and McGuire (72.7%) each had ~24-30% withhold votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300707,"accession_number":"0001628280-23-016825","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q1 revenue $4.1M, up 22% YoY; net loss $24M; FY23 guidance reaffirmed $23-25M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.1M, up 22% YoY driven by consumable kit sales including $1.3M related party.","Gross margin 51%; operating expenses $29.5M (up 18%) with $8.7M stock-based comp.","Net loss $24.0M compared to $23.6M in prior year quarter.","Cash and investments $410.5M as of March 31, 2023.","Full year 2023 revenue guidance reaffirmed $23M-$25M (48-61% growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":4053000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320661,"accession_number":"0001628280-23-006052","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q4 revenue $4.6M (+50% YoY); FY22 revenue $15.5M (+134%); guides FY23 $23-25M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $4.6M, up 50% from $3.1M in Q4 2021; product revenue $3.2M including $1.7M related party.","Full year 2022 revenue $15.5M, up 134% from $6.6M in 2021; net loss $93.0M vs $71.2M prior year.","Shipped 22 instruments in 2022, cumulative 39 as of Dec 31, 2022; gross margin 46% for full year.","Cash, equivalents and investments $426.4M as of Dec 31, 2022.","FY 2023 revenue guidance $23-25M, representing 48%-61% growth over 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338787,"accession_number":"0001628280-22-028914","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q3 revenue $4.0M, net loss $24.0M; FY2022 guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $4.0M, up 82% YoY from $2.2M, driven by Proteograph product suite sales.","Net loss of $24.0M vs $18.4M in Q3 2021; operating expenses $27.0M including $9.1M stock-based comp.","Gross margin 49%; cash, cash equivalents and investments $441.0M at Sep 30, 2022.","Full-year 2022 revenue guidance reaffirmed at $14.0M to $16.0M.","Published results in Advanced Materials; customer adoption increasing with multiple studies underway."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":10888000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356140,"accession_number":"0001628280-22-023754","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2022-08-26T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Seer President Omead Ostadan resigns; CEO Omid Farokhzad becomes President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ostadan resigns as President and from the Board effective Sep 30, 2022 for personal reasons.","Board size reduced from ten to nine members, effective Sep 30, 2022.","CEO Omid Farokhzad appointed President on top of his CEO and Chair roles, effective Ostadan's resignation.","Ostadan enters Consultant Agreement for up to 10 hrs/month at $1,000/hr to provide transition services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356139,"accession_number":"0001628280-22-021941","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q2 2022 revenue $3.6M, net loss $22.8M; guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.6M vs $1.3M YoY; product revenue $3.5M including $1.1M from related party.","Net loss $22.8M vs $16.6M YoY; operating expenses $25.0M up from $17.4M.","Cash, equivalents and investments $456.1M as of June 30, 2022.","FY 2022 revenue guidance reaffirmed at $14M-$16M.","Launched Proteograph Analysis Suite 2.0 for scalable proteogenomic analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":6934000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374502,"accession_number":"0001628280-22-017449","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Seer stockholders elect three directors, ratify Deloitte, approve say-on-pay every 3 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Robert S. Langer, Rachel Haurwitz, and Dipchand (Deep) Nishar as Class II directors; each received over 82% of votes cast.","Ratified Deloitte & Touche as independent auditor for fiscal year ending Dec 31, 2022; 81,003,353 for, 2,252 against.","Non-binding advisory vote selected 3-year frequency for say-on-pay; company will hold votes every three years until 2028.","Approximately 81.9% of eligible votes were represented, constituting a quorum at the Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374501,"accession_number":"0001628280-22-012287","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer reports Q1 revenue $3.3M, net loss $23.6M; reaffirms FY2022 guidance $14-16M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.3M (vs $62K Q1 2021); product revenue $3.2M incl. $1.1M related-party.","Net loss $23.6M (vs $16.4M); operating expenses $25.0M incl. $8.1M stock-based comp.","Cash, cash equivalents and investments $472M as of March 31, 2022.","FY2022 revenue guidance reaffirmed at $14.0-16.0M; increasing investments in commercial, R&D.","Hired Scott Thomas as Chief Commercial Officer; PNAS publication on Proteograph performance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":3312000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393006,"accession_number":"0001628280-22-006720","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2022-03-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Seer appoints Scott Thomas as Chief Commercial Officer effective March 21, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Thomas appointed CCO, effective March 21, 2022; previously SVP at Singular Genomics and various roles at Illumina.","Base salary of $395,000; target annual bonus of 40% of base salary, prorated for 2022.","Sign-on bonus of $50,000 (grossed up) subject to repayment if employment ends before two-year anniversary.","Initial equity grant recommended: stock option for 110,000 shares and RSU for 26,000 shares with time-based vesting.","Eligible for Key Executive Change in Control and Severance Plan with severance benefits for qualifying termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393005,"accession_number":"0001628280-22-004232","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q4 2021 rev $3.1M, FY rev $6.6M; guides FY2022 rev $14-16M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $3.1M (up from $336K YoY); net loss $19.7M vs $12.9M.","Full-year 2021 revenue $6.6M vs $656K; net loss $71.2M vs $32.8M.","Gross margin 47% in Q4, 52% for full year; cash+investments $493.3M.","Shipped 17 instruments through year-end 2021; broad commercial release of Proteograph commenced.","2022 revenue guidance $14-16M; expects to increase investments in commercial, ops, and R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":6617000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393004,"accession_number":"0001628280-22-003179","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2022-02-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Seer President & COO Omead Ostadan returns from leave, shifts to part-time for ~10 months","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ostadan returns Feb 28, 2022 as President on part-time (33% status) for ~10 months.","Base salary prorated to 33% of $464,546.63 annualized; bonus target remains at 45% of earned salary.","Equity vesting modified: certain RSU shares forfeited; options vest every third month during part-time.","Company will reimburse COBRA premiums for Ostadan and family during part-time period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393003,"accession_number":"0001628280-22-001143","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2022-01-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Seer appoints Meeta Gulyani to Audit Committee; Deep Nishar resigns from committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Meeta Gulyani appointed to Audit Committee effective January 18, 2022.","Deep Nishar resigned from Audit Committee; not due to any disagreement with the Company.","Board determined Gulyani qualifies as independent and meets audit committee financial literacy standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411465,"accession_number":"0001628280-21-024168","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2021-11-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Seer appoints Meeta Gulyani to Board of Directors; brings life sciences industry experience from Merck KGaA","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Meeta Gulyani as Class III director with term expiring at 2023 annual meeting.","Gulyani is EVP, Head of Strategy, Business Development & Transformation for Merck KGaA's Life Science business (MilliporeSigma).","Received initial stock option for 30,000 shares vesting monthly over 3 years; annual cash retainer of $40,000.","Board expanded from nine to ten directors effective November 29, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411464,"accession_number":"0001628280-21-022540","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q3 2021 revenue $2.2M, net loss $18.4M; on track for broad release in early 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.2M vs $72K in Q3 2020; product-related revenue $1.6M including $787K from related party.","Gross margin 54%; operating expenses $19.6M (up from $8.5M) due to higher compensation and public company costs.","Net loss $18.4M vs $8.2M; cash and investments $506.6M as of Sept 30, 2021.","Added new Limited Release customers; on track for high single-digit total; broad release expected early 2022.","Customer studies: Oregon Health (prostate cancer, 500-1000 samples), Broad Institute (proteome depth), Sanford Burnham (TMT), Protein Metrics (glycoproteome)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":3551000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411463,"accession_number":"0001628280-21-022257","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Seer appoints Rachel Haurwitz, Ph.D. to its board; David Singer resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Haurwitz, CEO of Caribou Biosciences, appointed to Seer board effective Nov. 8, 2021 as Class II director.","David Singer resigned as director effective Nov. 8; no dispute or disagreement with Seer.","Dr. Haurwitz receives standard non-employee director cash compensation of $40k/year plus initial option for 30,000 shares.","Deep Nishar replaces Singer on Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-08T23:59:59+00:00|411463"}